Trending...
- Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
- Peter J. D'Arruda Founder of Capital Financial Joins Tom Hegna on the Podcast "Financial Freedom with Tom Hegna"
GREENSBORO, N.C., Nov. 20, 2020 /PRNewswire/ -- Greensboro-based, Carolina Liquid Chemistries Corp. (CLC) has been tirelessly working since the beginning of the COVID-19 outbreak to provide high-quality testing kits and instruments to healthcare providers and laboratories as quickly as possible.
Continuing with these efforts, CLC distributes PCR and Extraction Instruments additional to their COVID-19 product offering. This includes the 3DMed ANDiS 380, which is a high-yield automated nucleic acid extraction system with a 96-well extractor. This instrument can run 96 extractions in 40 minutes and has an extremely high extraction efficiency, with a >95% recovery rate of magnetic beads.
CLC provides the Azure Cielo™ 6, a 96-Well Real-Time PCR System designed to be user-friendly with a large touch screen interface and software compatible with LIMS. The Azure Cielo™ 6 also contains optics and thermal blocks designed to deliver the same uniformity and reproducibility for high-throughput testing.
CLC also offers FDA Emergency Use Authorized Real-Time RT-PCR Test Kits. The QuantiVirus™ SARS-CoV-2 Test Kits from DiaCarta are based on real-time Reverse-Transcription Polymerase Chain Reaction (RT-PCR) technology, developed for specific detection of SARS-CoV-2 (COVID-19) viral RNA extracted from nasopharyngeal swabs, oropharyngeal, and sputum samples.
More on ncarol.com
Most notably, CLC offers the Point-of-Care/CLIA-Waived/Fingerstick Fastep® COVID-19 IgG/IgM Rapid Test Device by Assure Tech. This test has received FDA Emergency Use Authorization for use with fingerstick whole blood specimens at the point-of-care, i.e. in patient care settings operating under CLIA Certificate of Waiver such as doctor's offices, hospitals, urgent care centers, pharmacies, university health centers, and emergency rooms rather than having to be sent to a central lab. For all CLC COVID-19 products, please refer to www.carolinachemistries.com for instructions for use, fast facts for healthcare providers and patients, and EUA information.
All Emergency Use Authorized tests are authorized for the intended use provided by the FDA in the EUA; these EUAs can be found at www.carolinachemistries.com. These tests have not been FDA cleared or approved. Tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
More on ncarol.com
About Carolina Liquid Chemistries Corp.
Headquartered in Greensboro, NC, Carolina Liquid Chemistries Corp. (CLC) is an authorized manufacturer, re-packager, re-labeler and value-added distributor of chemistry systems and reagents, as well as COVID-19 testing supplies. CLC helps clinical laboratories of all sizes reduce chemistry analyzer and reagent costs, while also receiving accurate and timely results. The company has responded to the COVID-19 pandemic by bringing several PCR and antibody tests to market under the FDA's Emergency Use Authorization. For more information, visit carolinachemistries.com or email [email protected].
SOURCE Carolina Liquid Chemistries
Related Links
https://www.carolinachemistries.com/
Continuing with these efforts, CLC distributes PCR and Extraction Instruments additional to their COVID-19 product offering. This includes the 3DMed ANDiS 380, which is a high-yield automated nucleic acid extraction system with a 96-well extractor. This instrument can run 96 extractions in 40 minutes and has an extremely high extraction efficiency, with a >95% recovery rate of magnetic beads.
CLC provides the Azure Cielo™ 6, a 96-Well Real-Time PCR System designed to be user-friendly with a large touch screen interface and software compatible with LIMS. The Azure Cielo™ 6 also contains optics and thermal blocks designed to deliver the same uniformity and reproducibility for high-throughput testing.
CLC also offers FDA Emergency Use Authorized Real-Time RT-PCR Test Kits. The QuantiVirus™ SARS-CoV-2 Test Kits from DiaCarta are based on real-time Reverse-Transcription Polymerase Chain Reaction (RT-PCR) technology, developed for specific detection of SARS-CoV-2 (COVID-19) viral RNA extracted from nasopharyngeal swabs, oropharyngeal, and sputum samples.
More on ncarol.com
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
- Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
- Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club
Most notably, CLC offers the Point-of-Care/CLIA-Waived/Fingerstick Fastep® COVID-19 IgG/IgM Rapid Test Device by Assure Tech. This test has received FDA Emergency Use Authorization for use with fingerstick whole blood specimens at the point-of-care, i.e. in patient care settings operating under CLIA Certificate of Waiver such as doctor's offices, hospitals, urgent care centers, pharmacies, university health centers, and emergency rooms rather than having to be sent to a central lab. For all CLC COVID-19 products, please refer to www.carolinachemistries.com for instructions for use, fast facts for healthcare providers and patients, and EUA information.
All Emergency Use Authorized tests are authorized for the intended use provided by the FDA in the EUA; these EUAs can be found at www.carolinachemistries.com. These tests have not been FDA cleared or approved. Tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
More on ncarol.com
- A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration
- Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
- Local upholstery business expands services to meet growing demand in Shelby and Cleveland County
- NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
- Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
About Carolina Liquid Chemistries Corp.
Headquartered in Greensboro, NC, Carolina Liquid Chemistries Corp. (CLC) is an authorized manufacturer, re-packager, re-labeler and value-added distributor of chemistry systems and reagents, as well as COVID-19 testing supplies. CLC helps clinical laboratories of all sizes reduce chemistry analyzer and reagent costs, while also receiving accurate and timely results. The company has responded to the COVID-19 pandemic by bringing several PCR and antibody tests to market under the FDA's Emergency Use Authorization. For more information, visit carolinachemistries.com or email [email protected].
SOURCE Carolina Liquid Chemistries
Related Links
https://www.carolinachemistries.com/
Filed Under: Business
0 Comments
Latest on ncarol.com
- New Angles US Group Founder Alexander Harrington Receives Top U.S. Corporate Training Honor and Leads Asia-Pacific Engagements in Taiwan
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- UK Financial Ltd Sets Official 30-Day Conversion Deadline for Three Exchange Listed Tokens Ahead of Regulated Upgrade
- New Jersey Therapy and Life Coaching Unveils Original Dan Fenelon Mural in Voorhees New Jersey Therapy Office
- Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
- Peter J. D'Arruda Founder of Capital Financial Joins Tom Hegna on the Podcast "Financial Freedom with Tom Hegna"
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
- Run the Diamond Releases New Winter Workout Album for Baseball and Softball Athletes
- IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
- Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
- EnergyStrat Launches Global LNG Risk Outlook 2025–2030
- LTL Claims Ratio Index – Update 3Q25
- Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
- Billion Strong Foundation Upgrades 3X Skills + Career Finder and New AI Impact Engine
- Holiday Decorations Most Likely to Cause Injuries
- UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
- CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
- BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
- UK Financial Ltd Announces It's Official Corporate Headquarters In The United Kingdom
